ECSP034797A - DERIVADOS DIHIDRO-BENZO[b][1,4]DIAZEPIN-2-ONA COMO ANTAGONISTAS II MGLUR2 - Google Patents

DERIVADOS DIHIDRO-BENZO[b][1,4]DIAZEPIN-2-ONA COMO ANTAGONISTAS II MGLUR2

Info

Publication number
ECSP034797A
ECSP034797A EC2003004797A ECSP034797A ECSP034797A EC SP034797 A ECSP034797 A EC SP034797A EC 2003004797 A EC2003004797 A EC 2003004797A EC SP034797 A ECSP034797 A EC SP034797A EC SP034797 A ECSP034797 A EC SP034797A
Authority
EC
Ecuador
Prior art keywords
dihidro
mglur2
diazepin
ona
antagonists
Prior art date
Application number
EC2003004797A
Other languages
English (en)
Inventor
Jurgen Wichmann
Vincent Mutel
Geo Adam
Thomas Johannes Woltering
Erwin Goetschi
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP034797A publication Critical patent/ECSP034797A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/181,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

en donde R1, R2, R3, X e Y son como se ha definido en la especificación. La invención además se refiere a medicamentos que contienen estos compuestos, un procedimiento para su preparación y su uso para la preparación de medicamentos para el tratamiento o prevención de trastornos neurológicos agudos y/o crónicos.
EC2003004797A 2001-04-12 2003-10-08 DERIVADOS DIHIDRO-BENZO[b][1,4]DIAZEPIN-2-ONA COMO ANTAGONISTAS II MGLUR2 ECSP034797A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01109125 2001-04-12

Publications (1)

Publication Number Publication Date
ECSP034797A true ECSP034797A (es) 2003-12-01

Family

ID=8177126

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004797A ECSP034797A (es) 2001-04-12 2003-10-08 DERIVADOS DIHIDRO-BENZO[b][1,4]DIAZEPIN-2-ONA COMO ANTAGONISTAS II MGLUR2

Country Status (37)

Country Link
US (1) US6544985B2 (es)
EP (1) EP1379511B1 (es)
JP (1) JP4071115B2 (es)
KR (1) KR100566171B1 (es)
CN (1) CN1264825C (es)
AR (1) AR035816A1 (es)
AT (1) ATE299868T1 (es)
AU (1) AU2002312788B2 (es)
BG (1) BG108254A (es)
BR (1) BR0208891A (es)
CA (1) CA2442557C (es)
CZ (1) CZ20033003A3 (es)
DE (1) DE60205100T2 (es)
DK (1) DK1379511T3 (es)
EC (1) ECSP034797A (es)
ES (1) ES2246012T3 (es)
GT (1) GT200200073A (es)
HR (1) HRP20030792A2 (es)
HU (1) HUP0400851A3 (es)
IL (2) IL157873A0 (es)
JO (1) JO2285B1 (es)
MA (1) MA27012A1 (es)
MX (1) MXPA03009311A (es)
MY (1) MY140271A (es)
NO (1) NO20034576L (es)
NZ (1) NZ528315A (es)
PA (1) PA8543301A1 (es)
PE (1) PE20021041A1 (es)
PL (1) PL367064A1 (es)
PT (1) PT1379511E (es)
RU (1) RU2263112C2 (es)
SI (1) SI1379511T1 (es)
SK (1) SK13682003A3 (es)
UY (1) UY27258A1 (es)
WO (1) WO2002083652A1 (es)
YU (1) YU79003A (es)
ZA (1) ZA200307243B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE261945T1 (de) 1999-10-15 2004-04-15 Hoffmann La Roche Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
KR20090031962A (ko) * 2001-12-27 2009-03-30 다이쇼 세이야꾸 가부시끼가이샤 6-플루오로비시클로[3.1.0]헥산 유도체
DE60319812T2 (de) * 2002-03-28 2009-04-23 Wisys Technology Foundation, Inc., Madison Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen
EP1925614A1 (en) * 2002-03-28 2008-05-28 Wisys Technology Foundation, Inc. Anxiolytic agents with reduced sedative and ataxic effects
ES2293287T3 (es) * 2003-07-25 2008-03-16 F. Hoffmann-La Roche Ag Combinacion de antagonista de mglur2 y de inhibidor de ache para el tratamiento de trastornos neurologicos agudos y/o cronicos.
US7329662B2 (en) 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
US20060160823A1 (en) * 2004-05-28 2006-07-20 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmaceutical compositions of Posaconazole
BRPI0512330A (pt) * 2004-06-21 2008-02-26 Hoffmann La Roche derivados de pirazol-pirimidina
BRPI0607927A2 (pt) * 2005-02-11 2009-10-20 Hoffmann La Roche derivados de pirazol-pirimidina
WO2006099972A1 (en) 2005-03-23 2006-09-28 F. Hoffmann-La Roche Ag Acetylenyl-pyrazolo-pvrimidine derivatives as mglur2 antagonists
CA2612419C (en) * 2005-06-23 2017-06-13 Array Biopharma Inc. Process for preparing benzimidazole compounds
JP5048675B2 (ja) 2005-09-27 2012-10-17 エフ.ホフマン−ラ ロシュ アーゲー mGluR2アンタゴニストとしてのオキサジアゾリルピラゾロ−ピリミジン類
GB0600228D0 (en) * 2006-01-06 2006-02-15 Fermentas Uab Inactivation method
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200808751A (en) * 2006-04-13 2008-02-16 Astrazeneca Ab New compounds
AU2007299129A1 (en) * 2006-09-20 2008-03-27 F. Hoffmann-La Roche Ag 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
ES2369866T3 (es) 2007-04-19 2011-12-07 F. Hoffmann-La Roche Ag Derivados de dihidro-benzo[b][1,4]diazepin-2-ona-sulfonamida.
CN101801930B (zh) * 2007-09-14 2013-01-30 奥梅-杨森制药有限公司 1,3-二取代的-4-苯基-1h-吡啶-2-酮
PL2200985T3 (pl) 2007-09-14 2011-12-30 Ortho Mcneil Janssen Pharmaceuticals Inc 1,3-Dipodstawione-4-(arylo-X-fenylo)-1H-pirydyn-2-ony
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
CN101861316B (zh) 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5996532B2 (ja) 2010-07-15 2016-09-21 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 有害生物防除剤としての新規複素環式化合物
WO2012059431A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
WO2012059432A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
CA2834548C (en) 2011-04-28 2021-06-01 The Broad Institute, Inc. Inhibitors of histone deacetylase
JP5790195B2 (ja) * 2011-06-22 2015-10-07 セントラル硝子株式会社 ピラゾール化合物の製造方法
CA2847247C (en) * 2011-08-29 2019-10-15 Sanford-Burnham Medical Research Institute Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
EP2877444B1 (en) 2012-07-27 2020-09-02 The Broad Institute, Inc. Inhibitors of histone deacetylase
CN104736140A (zh) 2012-10-23 2015-06-24 霍夫曼-拉罗奇有限公司 用于治疗自闭症的mGlu2/3拮抗剂
US9914717B2 (en) 2012-12-20 2018-03-13 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
DK2940014T3 (en) * 2012-12-28 2018-12-10 Crystalgenomics Inc 2,3-DIHYDRO-ISOINDOL-1-ON DERIVATIVE AS BTK KINase INHIBITORS AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
MX386697B (es) 2014-01-21 2025-03-19 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
KR102736869B1 (ko) 2014-03-07 2024-12-02 바이오크리스트파마슈티컬즈,인코포레이티드 인간 혈장 칼리크레인 저해제
JP2017513844A (ja) * 2014-04-23 2017-06-01 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 知的障害の処置のためのmGlu2/3アンタゴニスト
WO2015191630A1 (en) 2014-06-10 2015-12-17 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof
CN108727345B (zh) * 2017-04-25 2023-06-27 广东东阳光药业有限公司 一种咪唑环中间体的制备方法
EP3737362B1 (en) 2018-01-12 2025-10-15 Kdac Therapeutics, Inc. Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
CN108586447B (zh) * 2018-01-19 2021-01-29 中国人民解放军第四军医大学 一种苯二氮杂卓化合物及其制备方法和应用
TWI855088B (zh) * 2019-06-06 2024-09-11 美商阿克思生物科學有限公司 製備胺基嘧啶化合物的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU224435B1 (hu) * 1995-02-09 2005-10-28 EGIS Gyógyszergyár Rt. Benzodiazepin-származékok, eljárás előállításukra, alkalmazásukra és ezeket tartalmazó gyógyászati készítmények
SK283859B6 (sk) * 1995-02-09 2004-03-02 Egis Gy�Gyszergy�R Rt. 1-[2'-(Substituovaný)vinyl]-5H-2,3-benzodiazepínové deriváty, spôsob ich prípravy a medziprodukty na ich prípravu, liečivá ich obsahujúce a ich použitie
MXPA02001340A (es) * 1999-08-05 2004-07-16 Prescient Neuropharma Inc Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos.
BR0014859A (pt) * 1999-10-15 2002-07-16 Hoffmann La Roche Derivados de benzodiazepina
ATE261945T1 (de) * 1999-10-15 2004-04-15 Hoffmann La Roche Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten

Also Published As

Publication number Publication date
AU2002312788B2 (en) 2005-11-10
MA27012A1 (fr) 2004-12-20
JP2004529925A (ja) 2004-09-30
ATE299868T1 (de) 2005-08-15
CA2442557C (en) 2008-12-23
PL367064A1 (en) 2005-02-21
YU79003A (sh) 2006-05-25
HUP0400851A2 (hu) 2004-07-28
JO2285B1 (en) 2005-09-12
MXPA03009311A (es) 2004-02-12
HRP20030792A2 (en) 2005-10-31
SK13682003A3 (sk) 2004-07-07
KR100566171B1 (ko) 2006-03-29
DK1379511T3 (da) 2005-11-07
GT200200073A (es) 2002-11-07
NZ528315A (en) 2005-04-29
RU2263112C2 (ru) 2005-10-27
US20020193367A1 (en) 2002-12-19
JP4071115B2 (ja) 2008-04-02
BR0208891A (pt) 2004-04-20
DE60205100T2 (de) 2006-06-01
ZA200307243B (en) 2004-12-16
KR20030087076A (ko) 2003-11-12
SI1379511T1 (en) 2005-10-31
WO2002083652A1 (en) 2002-10-24
UY27258A1 (es) 2002-10-31
IL157873A0 (en) 2004-03-28
CN1264825C (zh) 2006-07-19
ES2246012T3 (es) 2006-02-01
PE20021041A1 (es) 2002-11-19
CA2442557A1 (en) 2002-10-24
HUP0400851A3 (en) 2010-03-29
PA8543301A1 (es) 2003-01-24
EP1379511A1 (en) 2004-01-14
HK1068888A1 (en) 2005-05-06
DE60205100D1 (de) 2005-08-25
BG108254A (bg) 2004-09-30
AR035816A1 (es) 2004-07-14
NO20034576D0 (no) 2003-10-10
NO20034576L (no) 2003-11-12
PT1379511E (pt) 2005-10-31
RU2003130637A (ru) 2005-04-10
EP1379511B1 (en) 2005-07-20
IL157873A (en) 2008-11-26
CZ20033003A3 (cs) 2004-05-12
MY140271A (en) 2009-12-31
CN1535266A (zh) 2004-10-06
US6544985B2 (en) 2003-04-08

Similar Documents

Publication Publication Date Title
ECSP034797A (es) DERIVADOS DIHIDRO-BENZO[b][1,4]DIAZEPIN-2-ONA COMO ANTAGONISTAS II MGLUR2
ECSP034796A (es) DERIVADOS DIHIDRO-BENZO[b][1,4]DIAZEPIN-2-ONA ANTAGONISTAS I MGLUR2
PA8565901A1 (es) Derivados de dihidrobenzodiazepin-2-ona iii
ECSP066391A (es) [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
PE20020521A1 (es) Compuestos heterociclicos sustituidos para tratar la resistencia a multiples drogas
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
BR0209580A (pt) Derivados de ciclohexan-1, 4 diamina substituìdos
PA8462401A1 (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
AR028824A1 (es) Compuestos antagonistas npy-5 y su uso en la manufactura de medicamentos.
ECSP045139A (es) DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTICA DE MGluR5
SV2003001107A (es) Imidazotriazinas ref.lea 35368
ECSP024403A (es) Derivados de sulfonil-pirrolidina utiles para el tratamiento de desordenes neurologicos
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
ES2163407T3 (es) Derivados piperidinilos tiaciclicos.
ES2190246T3 (es) Nuevos compuestos de tiazolopirimidina.
DE60203797D1 (de) Benzo[d]azepin-derivative als 5-ht6-rezeptor-antagonisten
BRPI0418255A (pt) derivados de piperazina e piperidina n-substituìdos
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.
PA8487701A1 (es) Derivados de 3,3-biarilpiperidina y 2,2-biarilmorfolina
SE9901077D0 (sv) Novel use
PE20061318A1 (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos
ECSP044971A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson
DOP2001000140A (es) Aril y heteroarilsulfonatos
UY27394A1 (es) Pedidos con actividad anti- angiogéna.